ROIS, the CDMO arm of ROVI, has completed its acquisition of an injectable drug‑product manufacturing and packaging facility in Phoenix, Ariz., from Bristol Myers Squibb. The transaction marks a significant expansion for the company, which has operated primarily in Europe, and positions it to offer U.S.-based sterile manufacturing for the first time. The deal follows the company’s 2025 rebranding effort, which aimed to highlight ROIS’s ambition to become one of the world’s top three injectabl...